For country-specific search results please log in above
Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects.
|As advanced therapeutic modalities move from concept to clinic, new cell engineering approaches will emerge and mature. MaxCyte will continue to leverage their best-in-class electroporation technology and experience in the industry to support our partners in pushing the frontiers of bio-based medicines.
|For small to medium scale
|For complex proteins, vaccines and biologics
|For cGMP manufacturing of
|For gram scale
|Advance your research with an electroporator designed for reproducible, high-efficiency transfection of 75 thousand to 700 million cells
|Decrease development timelines and costs with efficient, reproducible transient transfection that can delay the need for stable cell line development
|Safely and efficiently transfect up to 20 billion cells with the only clinically validated electroporator developed with cell therapy in mind
|Accelerate recombinant protein development with the ability to transition seamlessly from discovery to manufacturing
Reagents & Supporting Products
‘Processing Assemblies’ for
R&D and cGMP development
|Reagents and accessories
for quick and easy
|Advance your project goals and milestones while maintaining the high levels of efficiency, viability, and consistency your therapy deserves.
|Develop protocols and handle precious samples confidently with one line of compatible reagents and accessories.